Drugs / TRB-061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934252 | May 2025 → Sep 2027 expected | atopic eczema | TRex Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-26 | TRex Bio, Inc. | Results TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis trex.bio ↗
Unblinded single- and multiple-dose results in healthy participants showed consistent pharmacokinetics and reproducible activation and expansion of immunoregulatory Tregs, supporting proof of mechanism for TRB-061 |
| 2026-05-07 | TRex Bio, Inc. | Results TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis trex.bio ↗
TRB-061, a novel TNFR2 agonist, induced selective Treg activity in vitro and pharmacodynamic expansion of tissue-licensed effector Tregs in non-human primates |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRB-061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06934252 ↗ |
| Route | Subcutaneous | “subcutaneously (SC) administered TRB-061” NCT06934252 ↗ |